Amplis was developed in response to the needs of clinicians specializing in Geriatrics, Primary Care, Neurology, Internal Medicine and Psychiatry.
Leading blood-brain-barrier knowledge
The blood-brain-barrier is a filtering system of the small blood vessels that carry blood to the brain and spinal cord tissue, blocking the passage of certain substances.
CNSdose has a world-leading understanding of how genetics influence this system. More specifically, CNSdose has an advanced understanding of the genetics of the ABC transporter pumps.
CNSdose uses the key to the blood brain barrier to create the Amplis report
We have the first positive clinical trial for antidepressant treatment. Evidence indicates our gene-guided treatment can double the likelihood of recovery. A review by the US Department of Veterans Affairs Health Administration said 'Amplis (antidepressant guidance) has the most favorable preliminary findings' based on this trial.
Depression is commonly associated with chronic diseases. Individuals diagnosed with common chronic conditions such as heart disease, arthritis, pain disorders, and chronic lung disease are at increased risk for developing depression. Individuals diagnosed with depression, are at increased risk for developing chronic conditions such as heart disease and diabetes. Amplis provides genetic guidance to assist in the management of these co-occurring chronic conditions.
With over 50% of US Adults taking two or more medications and 28% being hospitalized due to adverse drug interactions, polypharmacy issues are on the rise.
Amplis assists in the identification of potential drug-drug interactions and medication risks.
80% of patients with diabetes and 45% with coronary artery disease will experience depression but it can take months to find relief. Amplis provides an analysis of a patient’s medication profile to help you optimize the management of their chronic condition.
Mental illness is the leading cause of disability in the US. Depression is a common co-occurrence with other mental health conditions. 57% of US adults with schizophrenia have comorbid depression. Amplis is distinguished by guiding mental health prescribing through the use of our proprietary blood-brain-barrier genetic technology.